Therapeutic Applications of TRAIL Receptor Agonists in Cancer and Beyond

Pharmacology and Therapeutics - United Kingdom
doi 10.1016/j.pharmthera.2015.09.001
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Elsevier BV

Related search

Pharmacology and Therapeutic Applications of A3 Receptor Subtype

Current Topics in Medicinal Chemistry
MedicineDrug Discovery
2003English

Liver X Receptor Agonists as Potential Therapeutic Agents for Dyslipidemia and Atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular MedicineCardiology
2003English

TRAIL/Apo2L Ligand Selectively Induces Apoptosis and Overcomes Drug Resistance in Multiple Myeloma: Therapeutic Applications

Blood
BiochemistryImmunologyCell BiologyHematology
2001English

TRAIL-induced Apoptosis of Thyroid Cancer Cells: Potential for Therapeutic Intervention

Oncogene
Cancer ResearchGeneticsMolecular Biology
2000English

Immunoactive Effects of Cannabinoids: Considerations for the Therapeutic Use of Cannabinoid Receptor Agonists and Antagonists

International Immunopharmacology
AllergyImmunologyPharmacology
2010English

Surface TRAIL Decoy Receptor-4 Expression Is Correlated With TRAIL Resistance in McF7 Breast Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2005English

Emerging Non-Cancer Applications of Therapeutic Ultrasound

International Journal of Hyperthermia
MedicineCancer ResearchRadiologicalPhysiologyUltrasound Technology
2015English

Lysophosphatidic Acid Type 2 Receptor Agonists in Targeted Drug Development Offer Broad Therapeutic Potential

Journal of Lipid Research
BiochemistryEndocrinologyCell Biology
2019English

TRAIL-based Gene Delivery and Therapeutic Strategies

Acta Pharmacologica Sinica
MedicinePharmacology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy